The U.S. Food and Drug Administration (FDA) has approved a new drug to treat chronic myeloid leukemia (CML).
The FDA granted accelerated approval Wednesday to Bristol-Myers Squibb Co.'s drug, Sprycel (dasatinib), as an oral inhibitor of multiple tyrosine kinases, for the treatment of adults in all phases of CML, if they have shown resistance or intolerance to prior therapy
